At least five to six cases of the infection being reported every day at the Government Medical College Hospital in recent weeks

It is possible to end the transmission of hepatitis B and C and prevent further sickness and deaths from the diseases, but time, considerable resources, and attention to various barriers will be required, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Hepatitis B and C kill more than 20,000 people every year in the United States.

¿Podemos transmitir la hepatitis?

Systematic review produced by the EPPI-Centre in 2015.This systematic review aimed to evaluate the effect of HAART and ARV monotherapy on liver disease progression and liver-related mortality in individuals co-infected with HIV and hepatitis C, including in patients with haemophilia.

CD81 plays a central role in a variety of physiological and pathological processes. Recent structural analysis of CD81 indicates that it contains an intramembrane cholesterol-binding pocket and that interaction with cholesterol may regulate a conformational switch in the large extracellular domain of CD81. Therefore, CD81 possesses a potential cholesterol-sensing mechanism; however, its relevance for protein function is thus far unknown. In this study we investigate CD81 cholesterol sensing in the context of its activity as a receptor for hepatitis C virus (HCV). Structure-led mutagenesis of the cholesterol-binding pocket reduced CD81–cholesterol association but had disparate effects on HCV entry, both reducing and enhancing CD81 receptor activity. We reasoned that this could be explained by alterations in the consequences of cholesterol binding. To investigate this further we performed molecular dynamic simulations of CD81 with and without cholesterol; this identified a potential allosteric mechanism by which cholesterol binding regulates the conformation of CD81. To test this, we designed further mutations to force CD81 into either the open (cholesterol-unbound) or closed (cholesterol-bound) conformation. The open mutant of CD81 exhibited reduced HCV receptor activity, whereas the closed mutant enhanced activity. These data are consistent with cholesterol sensing switching CD81 between a receptor active and inactive state. CD81 interactome analysis also suggests that conformational switching may modulate the assembly of CD81–partner protein networks. This work furthers our understanding of the molecular mechanism of CD81 cholesterol sensing, how this relates to HCV entry, and CD81's function as a molecular scaffold; these insights are relevant to CD81's varied roles in both health and disease.

Withdrawn by Author.

Dover (May 4, 2022) – The Division of Public Health (DPH) is announcing May as Viral Hepatitis Awareness Month and May 19 as Hepatitis Testing Day. There are several different viruses that can cause hepatitis. The most common type of viral hepatitis are hepatitis A, hepatitis B, and hepatitis C. Both hepatitis A and hepatitis B […]

Title: Hepatitis E Vaccine Appears Safe, Effective
Category: Health News
Created: 8/23/2010 10:10:00 AM
Last Editorial Review: 8/24/2010 12:00:00 AM

Title: New Drug Combo Helps Hard-to-Treat Hepatitis C
Category: Health News
Created: 8/27/2013 4:36:00 PM
Last Editorial Review: 8/28/2013 12:00:00 AM

Title: Liver Damage From Hepatitis C More Widespread Than Thought
Category: Health News
Created: 8/27/2015 12:00:00 AM
Last Editorial Review: 8/27/2015 12:00:00 AM

Title: Test All U.S. Adults for Hepatitis C, Expert Panel Says
Category: Health News
Created: 8/27/2019 12:00:00 AM
Last Editorial Review: 8/28/2019 12:00:00 AM

Title: Hepatitis (Viral Hepatitis A, B, C, D, E, G)
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 8/8/2022 12:00:00 AM

Title: Hepatitis C Infection Can Kill, But Less Than a Third of Patients Get Treatment
Category: Health News
Created: 8/10/2022 12:00:00 AM
Last Editorial Review: 8/10/2022 12:00:00 AM

Highlights: Kolkata Municipal Corporation screens pregnant women for hepatitis B to prevent transmission to th

Delhi has experienced a substantial increase in medlinkHepatitis A/medlink cases over the past two months, according to doctors. Hepatitis (!--ref1--)

Patent holder and pharma major Gilead, announced voluntary licences with seven generic drug manufacturers in India to s

Two Hyderabad-based drug companies, Natco Pharma and Hetero have received approval for the sale of Hepatitis- C drug from the Drugs Controller General of India (DCGI).

Indian drug maker, Cipla has announced that it has released the generic version of Hepatitis C drug, Sofosbuvir in India.The drug will be marketed under

US pharmaceutical giant Gilead has obtained a patent for its Hepatitis C drug from India. This patent could potentially stop affordable copies reaching millions of people in other countries.

Deaths from viral hepatitis-related causes are increasing, with around one hepatitis death every 30 seconds, says the WHO, ahead of World Hepatitis Day (July 28).

Viral hepatitis is the name given to a viral infection that causes liver inflammation and damage. There are different types of hepatitis viruses that infect the liver out of which hepatitis A, B and C are the most common.

Researchers at Princeton and Rutgers universities have found that the hepatitis E virus — an emerging liver virus historically found in developing countries but now on the rise in Europe — uses a technique to spread infection that scientists could in fact exploit to treat the disease.

Berlin, May 5: Several drugs approved for the treatment of hepatitis C viral infection have been identified as potential candidates against COVID-19 caused by the SARS-CoV-2 coronavirus, according to a study based on extensive calculations using supercomputer simulations.

Viral hepatitis is the name given to a viral infection that causes liver inflammation and damage. There are different types of hepatitis viruses that infect the liver out of which hepatitis A, B and C are the most common.

The title compound, C15H22N4O5S, was prepared via alkyl­ation of 3-(chloro­meth­yl)-5-(pentan-3-yl)-1,2,4-oxa­diazole in anhydrous dioxane in the presence of tri­ethyl­amine. The thia­diazine ring has an envelope conformation with the S atom displaced by 0.4883 (6) Å from the mean plane through the other five atoms. The planar 1,2,4-oxa­diazole ring is inclined to the mean plane of the thia­diazine ring by 77.45 (11)°. In the crystal, mol­ecules are linked by C—H⋯N hydrogen bonds, forming chains propagating along the b-axis direction. Hirshfeld surface analysis and two-dimensional fingerprint plots have been used to analyse the inter­molecular contacts present in the crystal. Mol­ecular docking studies were use to evaluate the title compound as a potential system that inter­acts effectively with the capsid of the Hepatitis B virus (HBV), supported by an experimental in vitro HBV replication model.

It is possible to end the transmission of hepatitis B and C and prevent further sickness and deaths from the diseases, but time, considerable resources, and attention to various barriers will be required, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Hepatitis B and C kill more than 20,000 people every year in the United States.

A method of treating hepatitis virus infection is disclosed. The method comprising administering to a human subject in need of such treatment an effective hepatitis virus-combatting amount of an alkyl lipid or alkyl lipid derivative.

A method of treating hepatitis virus infection is disclosed. The method comprising administering to a human subject in need of such treatment an effective hepatitis virus-combatting amount of an alkyl lipid or alkyl lipid derivative.

Compounds of Formula I, including pharmaceutically acceptable salts, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:

A former patient at Launceston's first purpose-built infectious diseases hospital wants Tasmanians to heed the warnings to stay home and stay safe.

Health authorities urge more than 500 patients of a dental clinic in Far North Queensland to be tested for HIV and hepatitis as the clinic is investigated over its infection control practices.

Seven people who have eaten frozen pomegranate purchased at Coles have been diagnosed with a unique strain of hepatitis A, prompting a recall of what the company behind the product describes as "a relatively small batch".

Systematic review produced by the EPPI-Centre in 2015.This systematic review aimed to evaluate the effect of HAART and ARV monotherapy on liver disease progression and liver-related mortality in individuals co-infected with HIV and hepatitis C, including in patients with haemophilia.

Withdrawn by Author.

Nonalcoholic steatohepatitis has emerged as a major cause of liver diseases with no effective therapies. Here, we evaluate the efficacies and pharmacokinetics of B1344, a long-acting PEGylated FGF21 analog, in a nongenetically modified nonhuman primate species that underwent liver biopsy, and demonstrate the potential for efficacies in humans. B1344 is sufficient to selectively activate signaling from the βKlotho/FGFR1c receptor complex. In cynomolgus monkeys with nonalcoholic fatty liver disease, administration of B1344 via subcutaneous injection for eleven weeks caused a profound reduction of hepatic steatosis, inflammation and fibrosis, and amelioration of liver injury and hepatocyte death as evidenced by liver biopsy and biochemical analysis. Moreover, improvement of metabolic parameters was observed in the monkey, including reduction of body weight and improvement of lipid profiles and glycemic control. To determine the role of B1344 in the progression of murine NAFLD independent of obesity, administration of B1344 were performed in mice fed with methionine and choline deficiency diet. Consistently, B1344 administration prevented the mice from lipotoxicity damage and nonalcoholic steatohepatitis at a dose-dependent manner. These results provide preclinical validation for an innovative therapeutics to NAFLD, and support further clinical testing of B1344 for treating nonalcoholic steatohepatitis and other metabolic diseases in humans.

There’s been a lot of attention given to the new antirviral drugs which target Hepatitis C - partly because of the burden of infection of the disease, and the lack of a treatment that can be made easily accessible to around the world, and partly because of the incredible cost of a course of treatment. But a new article on BMJ talks about the...

Rafael Simó
Sep 1, 1996; 19:998-1000
Short Report

Combination therapy with interferon beta-1b plus lopinavir-ritonavir and ribavirin appears to improve symptoms and shorten hospital stays for people with mild to moderate COVID-19.

OBJECTIVE

To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM).

Hepatitis A infection causes severe disease among adolescents and adults. Hepatitis A vaccination (HepA) is recommended universally at 1 year, with vaccination through 18 years based on risk or desire for protection.

This is the first study to evaluate adolescent HepA coverage in the United States using provider-reported vaccination data. HepA coverage was low among adolescents, leaving a large population susceptible to hepatitis A infection maturing into adulthood. (Read the full article)

Infants born to women who are hepatitis B surface antigen–positive have a 90% risk of chronic hepatitis B virus infection, which may cause premature death from liver failure or cancer. Postexposure prophylaxis in infancy prevents 85% to 95% of perinatal infections.

The Perinatal Hepatitis B Prevention Program was created to identify and manage infants born to women who are hepatitis B surface antigen–positive. We provide, for the first time since 1996, national-level data on the outcomes of the Perinatal Hepatitis B Prevention Program. (Read the full article)

Universal hepatitis B virus (HBV) vaccination is a cost-effective strategy to control HBV infection. Giving hepatitis B immunoglobulin to neonates of HBV carrier mothers additionally reduces transmission but is not widely used because of its expense and infrastructure requirements.

Maternal screening for hepatitis B surface antigen and hepatitis B immunoglobulin treatment of neonates of hepatitis B virus carrier mothers could be a cost-effective addition to universal vaccination in settings in which health infrastructure can support such an intervention. (Read the full article)